How Regeneron's Covid Drug Lent Itself To A Big Third-Quarter Beat

Regeneron stock popped early Thursday after the company reported adjusted income of $15.37 per share on $3.45 billion in third-quarter sales.

On average, analysts polled by FactSet expected Regeneron Pharmaceuticals (REGN) to earn $10.23 per share on $2.75 billion in sales. The third-quarter beat included $804 million from Regeneron's Covid treatment, an antibody cocktail.